MA46034A - Formulation pharmaceutique stable comprenant une composition de surfactant pulmonaire reconstitué - Google Patents

Formulation pharmaceutique stable comprenant une composition de surfactant pulmonaire reconstitué

Info

Publication number
MA46034A
MA46034A MA046034A MA46034A MA46034A MA 46034 A MA46034 A MA 46034A MA 046034 A MA046034 A MA 046034A MA 46034 A MA46034 A MA 46034A MA 46034 A MA46034 A MA 46034A
Authority
MA
Morocco
Prior art keywords
composition
pharmaceutical formulation
formulation including
stable pharmaceutical
pulmonary surfactant
Prior art date
Application number
MA046034A
Other languages
English (en)
Inventor
Marisa Pertile
Franco Sartor
Raschini Annamaria Soliani
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA46034A publication Critical patent/MA46034A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395Alveolar surfactant peptides; Pulmonary surfactant peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0082Lung surfactant, artificial mucus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA046034A 2016-08-24 2017-08-09 Formulation pharmaceutique stable comprenant une composition de surfactant pulmonaire reconstitué MA46034A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16185516 2016-08-24

Publications (1)

Publication Number Publication Date
MA46034A true MA46034A (fr) 2021-04-28

Family

ID=56800200

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046034A MA46034A (fr) 2016-08-24 2017-08-09 Formulation pharmaceutique stable comprenant une composition de surfactant pulmonaire reconstitué

Country Status (12)

Country Link
US (1) US10543256B2 (fr)
EP (1) EP3503905A1 (fr)
KR (1) KR102395835B1 (fr)
CN (1) CN109562139A (fr)
AR (1) AR109386A1 (fr)
BR (1) BR112019003673A2 (fr)
CA (1) CA3029456A1 (fr)
MA (1) MA46034A (fr)
MX (1) MX2019001854A (fr)
RU (1) RU2748417C2 (fr)
TW (1) TW201811311A (fr)
WO (1) WO2018036819A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021151853A1 (fr) * 2020-01-28 2021-08-05 Chiesi Farmaceutici S.P.A. Polypeptides ayant des propriétés améliorées
CN114159546B (zh) * 2021-12-20 2024-06-04 北京双鹤润创科技有限公司 新一代合成肺表面活性物质制剂及其临床应用
CN115300635B (zh) * 2022-08-10 2026-02-10 广州医科大学 治疗肺动脉高压的吸入剂的仿生肺表面活性物载体和药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260273A (en) 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
CA2063273C (fr) * 1989-07-11 2002-09-24 Bradley J. Benson Surfactants pulmonaires et methodes
EP0976403A1 (fr) * 1998-07-30 2000-02-02 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Adjuvant contenant un surfactant pulmonaire
EP1189625A1 (fr) 1999-06-11 2002-03-27 Byk Gulden Lomberg Chemische Fabrik GmbH Preparation pharmaceutique contenant des modifications de la proteine b du surfactant (sp-b) et de la proteine c du surfactant (sp-c)
EP1214056B1 (fr) * 1999-09-24 2003-10-29 Alcon Inc. Formulations topiques sous forme de suspension contenant de la ciprofloxacine et de la dexamethasone
US20050031706A1 (en) * 2003-08-06 2005-02-10 Pena Lorraine E. Viscosity-stable compositions useful for treating gastrointestinal disorders
EP2049554A4 (fr) 2006-07-20 2011-06-29 Univ Rochester Medical Ct Tensioactif pulmonaire synthetique et utilisation associée
RS53172B (sr) 2006-10-13 2014-06-30 Chiesi Farmaceutici S.P.A. Rekonstituisani surfaktanti sa poboljšanim svojstvima
US8399406B2 (en) * 2009-06-05 2013-03-19 Chiesi Farmaceutici S.P.A. Reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C)
CN102049040A (zh) * 2009-10-30 2011-05-11 北京隆旗生物科技有限公司 人工表面活性物质混合液及其制备与应用
RU2656185C2 (ru) * 2012-11-21 2018-05-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Реконструированные сурфактанты легких
US10738079B2 (en) * 2017-04-14 2020-08-11 Emory University Compositions and methods for managing respiratory conditions

Also Published As

Publication number Publication date
RU2748417C2 (ru) 2021-05-25
BR112019003673A2 (pt) 2019-05-21
RU2019107379A (ru) 2020-09-25
AR109386A1 (es) 2018-11-28
TW201811311A (zh) 2018-04-01
MX2019001854A (es) 2019-11-11
CA3029456A1 (fr) 2018-03-01
US10543256B2 (en) 2020-01-28
RU2019107379A3 (fr) 2020-11-23
CN109562139A (zh) 2019-04-02
KR20190039933A (ko) 2019-04-16
KR102395835B1 (ko) 2022-05-10
EP3503905A1 (fr) 2019-07-03
US20180055914A1 (en) 2018-03-01
WO2018036819A1 (fr) 2018-03-01

Similar Documents

Publication Publication Date Title
MA47816A (fr) Composition pharmaceutique comprenant du sélexipag
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA53243A (fr) Compositions comprenant une combinaison de ipilimumab et nivolumab
EP3493799A4 (fr) Composition pharmaceutique decannabis
EP3432870A4 (fr) Compositions comprenant de la choline
EP3368555A4 (fr) Protéines à double fonction et composition pharmaceutique comprenant ces dernières
EP3344066A4 (fr) Compositions de boissons stables prêtes à boire comprenant des agents actifs lipophiles
PT3442586T (pt) Formulação parentérica estável de nimodipina
EP3493798A4 (fr) Composition pharmaceutique decannabis
EP3496753A4 (fr) Formulation d'anticorps anti-pd-1
EP3454899C0 (fr) Composition pharmaceutique
LT3116491T (lt) Terapiškai aktyvių junginių farmacinės kompozicijos
MA43705A (fr) Formulation pharmaceutique
DK3634377T3 (da) Farmaceutisk formulering
EP3429589A4 (fr) Composition pharmaceutique du nilotinib
EP3402470A4 (fr) Composition pharmaceutique stable
MA47516A (fr) Composition pharmaceutique
MA40982A (fr) Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
DK3400017T3 (da) Kontinuerlig kompleksering af aktive farmaceutiske ingredienser
MA49822A (fr) Combinaison pharmaceutique comprenant du ponesimod
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen
MA46034A (fr) Formulation pharmaceutique stable comprenant une composition de surfactant pulmonaire reconstitué
EP3646863A4 (fr) Composition pharmaceutique
EP3646867A4 (fr) Composition pharmaceutique
LT3582617T (lt) Pesticidinių piridazinpirazolamidų stabili kompozicija